title: Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes.
abstract: BACKGROUND
  Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH, may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH concentrations and aggregation propensity in blood from patients with type-2 diabetes.
  
  
  METHODS
  Blood samples (n = 13) were incubated (2 h, 37°C) with NAC (10-100 micromolar) in vitro. Platelet aggregation in response to thrombin and ADP (whole blood aggregometry) was assessed, together with platelet GSH concentration (reduced and oxidized), antioxidant status, reactive oxygen species (ROS) generation, and plasma NOx (a surrogate measure of platelet-derived nitric oxide; NO).
  
  
  RESULTS
  At therapeutically relevant concentrations (10-100 micromolar), NAC increased intraplatelet GSH levels, enhanced the antioxidant effects of platelets, and reduced ROS generation in blood from type-2 diabetes patients. Critically, NAC inhibited thrombin- and ADP-induced platelet aggregation in vitro. Plasma NOx was enhanced by 30 micromolar NAC.
  
  
  CONCLUSIONS
  Our results suggest that NAC reduces thrombotic propensity in type-2 diabetes patients by increasing platelet antioxidant status as a result of elevated GSH synthesis, thereby lowering platelet-derived ROS. This may increase bioavailability of protective NO in a narrow therapeutic range. Therefore, NAC might represent an alternative or additional therapy to aspirin that could reduce thrombotic risk in type-2 diabetes.
authors: Free Radical Research Facility, Department of Diabetes & Cardiovascular Science, University of the Highlands & Islands, Inverness, Scotland, UK.
authors: Kyle R
authors: KR
authors: Gibson
authors: Tim J
authors: TJ
authors: Winterburn
authors: Fiona
authors: F
authors: Barrett
authors: Sushma
authors: S
authors: Sharma
authors: Sandra M
authors: SM
authors: MacRury
authors: Ian L
authors: IL
authors: Megson
references: J Intern Med. 2002 May;251(5):437-46
references: 11982744
references: J Inorg Biochem. 2004 Nov;98(11):1696-702
references: 15522397
references: Clin Chem. 2002 Mar;48(3):570-3
references: 11861453
references: Am J Hypertens. 2005 Jun;18(6):839-43
references: 15925745
references: Diabetes Care. 2008 May;31(5):940-4
references: 18268065
references: Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):245-51
references: 7606199
references: Clin Biochem. 1997 Oct;30(7):509-15
references: 9399018
references: Methods Mol Biol. 2004;279:81-103
references: 15199238
references: Antioxid Redox Signal. 2008 Sep;10(9):1631-74
references: 18598143
references: Nature. 2006 Apr 13;440(7086):944-8
references: 16612386
references: Thromb Res. 2003 Apr 15;110(1):39-46
references: 12877907
references: J Cardiovasc Pharmacol. 2009 Oct;54(4):319-26
references: 19668088
references: J Immunol. 1994 Jun 15;152(12):5796-805
references: 8207209
references: J Endocrinol Invest. 2009 Apr;32(4):352-6
references: 19636205
references: Br J Clin Pharmacol. 2006 Jan;61(1):5-15
references: 16390346
references: J Thromb Haemost. 2004 Aug;2(8):1282-91
references: 15304032
references: JAMA. 2008 Nov 12;300(18):2134-41
references: 18997198
references: Nat Protoc. 2006;1(6):3159-65
references: 17406579
references: Diabetologia. 1999 Feb;42(2):167-76
references: 10064096
references: J Cardiovasc Pharmacol. 1998 Jul;32(1):101-5
references: 9676728
references: J Endocrinol Invest. 2001 Jan;24(1):37-41
references: 11227730
references: J Cardiovasc Pharmacol. 2001 Jan;37(1):1-5
references: 11152366
references: BMJ. 2008 Oct 16;337:a1840
references: 18927173
references: Thromb Res. 1994 Dec 1;76(5):451-61
references: 7900093
references: J Am Soc Nephrol. 2005 Aug;16(8):2346-53
references: 15944340